Elanco’s Ascend Initiative: Can AI & Digitization Help Improve Their Profitability?

Elanco Animal Health’s earnings for the second quarter of 2025 reveal a nuanced landscape of growth and challenges. On the positive side, Elanco experienced strong growth in its organic constant currency, posting an 8% increase and exceeding guidance across revenue, adjusted EBITDA, and adjusted EPS. This growth was largely fueled by the success in the U.S. Pet Health sector, which surged by 11%, marking the eighth consecutive quarter of underlying growth. Innovation played a critical role, bringing in $420 million during the first half of the year. The company has raised its full-year innovation revenue forecast to $720-800 million, signaling robust market performance.